Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1948 1
1951 2
1959 1
1960 1
1961 1
1998 4
1999 7
2000 4
2001 4
2002 12
2003 26
2004 31
2005 32
2006 38
2007 44
2008 45
2009 53
2010 55
2011 54
2012 69
2013 77
2014 95
2015 87
2016 113
2017 92
2018 101
2019 97
2020 86
2021 90
2022 83
2023 82
2024 35

Text availability

Article attribute

Article type

Publication date

Search Results

1,319 results

Results by year

Filters applied: . Clear all
Page 1
Aprepitant, fosaprepitant and risk of ifosfamide-induced neurotoxicity: a systematic review.
Vazirian F, Samadi S, Rahimi H, Sadeghi M, Mohammadpour AH. Vazirian F, et al. Cancer Chemother Pharmacol. 2022 Jul;90(1):1-6. doi: 10.1007/s00280-022-04439-x. Epub 2022 May 30. Cancer Chemother Pharmacol. 2022. PMID: 35635561 Review.
Ifosfamide is one of the chemotherapy regimens which potentially causes neurotoxicity in patients up to 30%. Aprepitant is administered as an anti-emetic agent in chemotherapy and regarding the inhibitory effect on CYP3A4, aprepitant can increase the risk of ifosfam …
Ifosfamide is one of the chemotherapy regimens which potentially causes neurotoxicity in patients up to 30%. Aprepitant is administer …
A pharmacological overview of aprepitant for the prevention of postoperative nausea and vomiting.
Padilla A, Habib AS. Padilla A, et al. Expert Rev Clin Pharmacol. 2023 Jan-Jun;16(6):491-505. doi: 10.1080/17512433.2023.2209722. Epub 2023 May 8. Expert Rev Clin Pharmacol. 2023. PMID: 37128935 Review.
Data on antiemetic combinations involving aprepitant are limited, and it is not clear if the addition of other antiemetics to aprepitant results in improved PONV prophylaxis. ...Aprepitant remains more expensive than other antiemetics, and there are no studie …
Data on antiemetic combinations involving aprepitant are limited, and it is not clear if the addition of other antiemetics to apre …
Aprepitant for the Treatment of Chronic Refractory Pruritus.
He A, Alhariri JM, Sweren RJ, Kwatra MM, Kwatra SG. He A, et al. Biomed Res Int. 2017;2017:4790810. doi: 10.1155/2017/4790810. Epub 2017 Sep 19. Biomed Res Int. 2017. PMID: 29057261 Free PMC article. Review.
Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that aprepitant is an alternative for patients suffering from pruritus who do not obtain enough symptom relief from conventional therapy....
Herein, we evaluate aprepitant's antipruritic effects and discuss its mechanism of action and adverse effects. We propose that apr …
Aprepitant for postoperative nausea and vomiting: a systematic review and meta-analysis.
Singh PM, Borle A, Rewari V, Makkar JK, Trikha A, Sinha AC, Goudra B. Singh PM, et al. Postgrad Med J. 2016 Feb;92(1084):87-98. doi: 10.1136/postgradmedj-2015-133515. Epub 2015 Dec 1. Postgrad Med J. 2016. PMID: 26627976 Review.
A systematic review was performed after searching a number of medical databases for controlled trials comparing aprepitant with conventional antiemetics published up to 25 April 2015 using the following keywords: 'Aprepitant for PONV', 'Aprepitant versus 5-HT …
A systematic review was performed after searching a number of medical databases for controlled trials comparing aprepitant with conve …
Aprepitant and fosaprepitant: a 10-year review of efficacy and safety.
Aapro M, Carides A, Rapoport BL, Schmoll HJ, Zhang L, Warr D. Aapro M, et al. Oncologist. 2015 Apr;20(4):450-8. doi: 10.1634/theoncologist.2014-0229. Epub 2015 Mar 20. Oncologist. 2015. PMID: 25795636 Free PMC article. Review.
This review examined accumulated data regarding the safety and efficacy of aprepitant and fosaprepitant over the decade since the first regulatory approval. ...In addition, their use as antiemetic therapy in special patient populations was highlighted. Future perspectives …
This review examined accumulated data regarding the safety and efficacy of aprepitant and fosaprepitant over the decade since the fir …
Aprepitant--a novel NK1-receptor antagonist.
Patel L, Lindley C. Patel L, et al. Expert Opin Pharmacother. 2003 Dec;4(12):2279-96. doi: 10.1517/14656566.4.12.2279. Expert Opin Pharmacother. 2003. PMID: 14640927 Review.
Recently, a new class of agents, the substance P antagonists, has heralded a novel approach for the control of emesis. Aprepitant (Emend, Merck & Co., Inc.), the first of this class, was recently approved by the FDA for the prevention of both acute and delayed chemothe …
Recently, a new class of agents, the substance P antagonists, has heralded a novel approach for the control of emesis. Aprepitant (Em …
Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting.
Dando TM, Perry CM. Dando TM, et al. Drugs. 2004;64(7):777-94. doi: 10.2165/00003495-200464070-00013. Drugs. 2004. PMID: 15025555 Review.
Aprepitant (Emend) is the first commercially available drug from a new class of agents, the neurokinin NK(1) receptor antagonists. ...Thus, aprepitant has the potential to interact with other agents metabolised by hepatic CYP isoenzymes. ...
Aprepitant (Emend) is the first commercially available drug from a new class of agents, the neurokinin NK(1) receptor antagonists. .. …
Aprepitant inhibits the development and metastasis of gallbladder cancer via ROS and MAPK activation.
Cao X, Yang Y, Zhou W, Wang Y, Wang X, Ge X, Wang F, Zhou F, Deng X, Miao L. Cao X, et al. BMC Cancer. 2023 May 23;23(1):471. doi: 10.1186/s12885-023-10954-8. BMC Cancer. 2023. PMID: 37221457 Free PMC article.
However, the effect of aprepitant on gallbladder cancer (GBC) is not clear yet. This study aimed to investigate the anti-tumor activity of aprepitant on GBC and the potential mechanisms. ...Consistently, aprepitant suppressed the growth of GBC in xenograft mi …
However, the effect of aprepitant on gallbladder cancer (GBC) is not clear yet. This study aimed to investigate the anti-tumor activi …
Drug-drug interactions with aprepitant in antiemetic prophylaxis for chemotherapy.
Schoffelen R, Lankheet AG, van Herpen CML, van der Hoeven JJM, Desar IME, Kramers C. Schoffelen R, et al. Neth J Med. 2018 Apr;76(3):109-114. Neth J Med. 2018. PMID: 29667586 Free article. Review.
Aprepitant can influence the pharmacokinetics of other drugs, as it is an inhibitor and inducer of CYP3A4. ...We give an overview of the metabolism and current data on clinically relevant drug-drug interactions with aprepitant during chemotherapy. Physicians should …
Aprepitant can influence the pharmacokinetics of other drugs, as it is an inhibitor and inducer of CYP3A4. ...We give an overview of …
Aprepitant: A New Modality for the Prevention of Postoperative Nausea and Vomiting: An Evidence-Based Review.
Milnes V, Gonzalez A, Amos V. Milnes V, et al. J Perianesth Nurs. 2015 Oct;30(5):406-17. doi: 10.1016/j.jopan.2014.11.013. J Perianesth Nurs. 2015. PMID: 26408515 Review.
RESULTS: Eight randomized controlled trials, one prognostic study, and one post hoc analysis were appraised. Perioperatively, aprepitant decreased the severity and number of episodes of PONV. DISCUSSION: Aprepitant appears to be more effective in decreasing the inci …
RESULTS: Eight randomized controlled trials, one prognostic study, and one post hoc analysis were appraised. Perioperatively, aprepitant …
1,319 results